Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

FEBS Lett. 2011 Dec 1;585(23):3699-709. doi: 10.1016/j.febslet.2011.03.023. Epub 2011 Mar 21.


Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL-6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology*
  • Humans
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Models, Immunological
  • Receptors, Interleukin-6 / antagonists & inhibitors*
  • Receptors, Interleukin-6 / immunology*


  • Antibodies, Monoclonal, Humanized
  • Receptors, Interleukin-6
  • tocilizumab